

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																																
NATURE OF CONVEYANCE:	ASSIGNMENT																																
CONVEYING PARTY DATA																																	
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>CYLENE PHARMACEUTICALS, INC.</td> <td>04/29/2013</td> </tr> </tbody> </table>		Name	Execution Date	CYLENE PHARMACEUTICALS, INC.	04/29/2013																												
Name	Execution Date																																
CYLENE PHARMACEUTICALS, INC.	04/29/2013																																
RECEIVING PARTY DATA																																	
<table border="1"> <tr> <td>Name:</td> <td>SENHWA BIOSCIENCES, INC.</td> </tr> <tr> <td>Street Address:</td> <td>9F, No. 205-1, Peishin Road, Section 3</td> </tr> <tr> <td>Internal Address:</td> <td>Hsintien district</td> </tr> <tr> <td>City:</td> <td>new Taipei City</td> </tr> <tr> <td>State/Country:</td> <td>TAIWAN</td> </tr> </table>		Name:	SENHWA BIOSCIENCES, INC.	Street Address:	9F, No. 205-1, Peishin Road, Section 3	Internal Address:	Hsintien district	City:	new Taipei City	State/Country:	TAIWAN																						
Name:	SENHWA BIOSCIENCES, INC.																																
Street Address:	9F, No. 205-1, Peishin Road, Section 3																																
Internal Address:	Hsintien district																																
City:	new Taipei City																																
State/Country:	TAIWAN																																
PROPERTY NUMBERS Total: 77																																	
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>61143282</td> </tr> <tr> <td>Application Number:</td> <td>61228121</td> </tr> <tr> <td>Application Number:</td> <td>61262079</td> </tr> <tr> <td>Application Number:</td> <td>12684053</td> </tr> <tr> <td>Application Number:</td> <td>60842061</td> </tr> <tr> <td>Application Number:</td> <td>60844542</td> </tr> <tr> <td>Application Number:</td> <td>60846683</td> </tr> <tr> <td>Application Number:</td> <td>60873936</td> </tr> <tr> <td>Application Number:</td> <td>60895716</td> </tr> <tr> <td>Application Number:</td> <td>11849230</td> </tr> <tr> <td>Application Number:</td> <td>13035640</td> </tr> <tr> <td>Application Number:</td> <td>60969556</td> </tr> <tr> <td>Application Number:</td> <td>12201892</td> </tr> <tr> <td>Application Number:</td> <td>12396084</td> </tr> <tr> <td>Application Number:</td> <td>13315103</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	61143282	Application Number:	61228121	Application Number:	61262079	Application Number:	12684053	Application Number:	60842061	Application Number:	60844542	Application Number:	60846683	Application Number:	60873936	Application Number:	60895716	Application Number:	11849230	Application Number:	13035640	Application Number:	60969556	Application Number:	12201892	Application Number:	12396084	Application Number:	13315103
Property Type	Number																																
Application Number:	61143282																																
Application Number:	61228121																																
Application Number:	61262079																																
Application Number:	12684053																																
Application Number:	60842061																																
Application Number:	60844542																																
Application Number:	60846683																																
Application Number:	60873936																																
Application Number:	60895716																																
Application Number:	11849230																																
Application Number:	13035640																																
Application Number:	60969556																																
Application Number:	12201892																																
Application Number:	12396084																																
Application Number:	13315103																																

CH \$3080.00 61143282

Application Number:	61170468
Application Number:	61240165
Application Number:	61242227
Application Number:	61297669
Application Number:	12762038
Application Number:	61180090
Application Number:	61218318
Application Number:	12784271
Application Number:	61179996
Application Number:	61218314
Application Number:	12819091
Application Number:	12879851
Application Number:	13207700
Application Number:	61180099
Application Number:	61218347
Application Number:	61287646
Application Number:	12784055
Application Number:	61263638
Application Number:	61237227
Application Number:	61289317
Application Number:	12869335
Application Number:	61243107
Application Number:	12883703
Application Number:	61248270
Application Number:	61255805
Application Number:	61323771
Application Number:	61380685
Application Number:	12897640
Application Number:	61243104
Application Number:	12883688
Application Number:	61266801
Application Number:	61354165
Application Number:	12946759
Application Number:	61405815
Application Number:	13242525

	61494660
Application Number:	60611030
Application Number:	60638603
Application Number:	60688796
Application Number:	60688986
Application Number:	11149007
Application Number:	11228636
Application Number:	60705966
Application Number:	11499076
Application Number:	12274302
Application Number:	60801550
Application Number:	12301090
Application Number:	60811990
Application Number:	12303952
Application Number:	60811992
Application Number:	60904694
Application Number:	12303957
Application Number:	60912411
Application Number:	12596240
Application Number:	60978042
Application Number:	61038681
Application Number:	61045933
Application Number:	12245619
Application Number:	13043956
Application Number:	61067845
Application Number:	61103908
Application Number:	12952879

CORRESPONDENCE DATA

Fax Number: 2028427899
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 202-842-7800
Email: cphillipnouchet@cooley.com, zpatdcdocting@cooley.com
Correspondent Name: Cooley LLP
Address Line 1: 1299 Pennsylvania Avenue NW, Suite 700
Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:

PATENT
REEL: 030554 FRAME: 0303

	SENHWA (319840-2000)
NAME OF SUBMITTER:	Yong Lu
Signature:	/Yong Lu/
Date:	06/05/2013

Total Attachments: 29

source=Cylene_Senhwa_Assignment #page1.tif
source=Cylene_Senhwa_Assignment #page2.tif
source=Cylene_Senhwa_Assignment #page3.tif
source=Cylene_Senhwa_Assignment #page4.tif
source=Cylene_Senhwa_Assignment #page5.tif
source=Cylene_Senhwa_Assignment #page6.tif
source=Cylene_Senhwa_Assignment #page7.tif
source=Cylene_Senhwa_Assignment #page8.tif
source=Cylene_Senhwa_Assignment #page9.tif
source=Cylene_Senhwa_Assignment #page10.tif
source=Cylene_Senhwa_Assignment #page11.tif
source=Cylene_Senhwa_Assignment #page12.tif
source=Cylene_Senhwa_Assignment #page13.tif
source=Cylene_Senhwa_Assignment #page14.tif
source=Cylene_Senhwa_Assignment #page15.tif
source=Cylene_Senhwa_Assignment #page16.tif
source=Cylene_Senhwa_Assignment #page17.tif
source=Cylene_Senhwa_Assignment #page18.tif
source=Cylene_Senhwa_Assignment #page19.tif
source=Cylene_Senhwa_Assignment #page20.tif
source=Cylene_Senhwa_Assignment #page21.tif
source=Cylene_Senhwa_Assignment #page22.tif
source=Cylene_Senhwa_Assignment #page23.tif
source=Cylene_Senhwa_Assignment #page24.tif
source=Cylene_Senhwa_Assignment #page25.tif
source=Cylene_Senhwa_Assignment #page26.tif
source=Cylene_Senhwa_Assignment #page27.tif
source=Cylene_Senhwa_Assignment #page28.tif
source=Cylene_Senhwa_Assignment #page29.tif

Exhibit B
Form of Patent Assignment Agreement

PATENT ASSIGNMENT

This Patent Assignment ("Assignment") is made and entered into as of April 30, 2013 by and between Cylene Pharmaceuticals, Inc. ("Assignor"), and Senhwa Biosciences, Inc. ("Assignee").

RECITALS

A. Assignor and Assignee are parties to that certain Asset Purchase and Sale Agreement (the "Purchase Agreement") entered into on April 30, 2013, pursuant to which Assignor has agreed to sell to Assignee and Assignee has agreed to purchase from Assignor various assets, including, without limitation, the Cylene Patent Rights set forth on Schedule A hereto (the "Patents").

B. All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Purchase Agreement.

C. Assignee desires to acquire Assignor's entire right, title and interest in and to the Patents.

NOW, THEREFORE, for good and valuable consideration provided pursuant to the Purchase Agreement, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree as follows:

1. **ASSIGNMENT.** Assignor has assigned and/or by these presents does hereby sell, assign, transfer and convey unto Assignee, the whole and entire right, title and interest (i) in and to the Patents, for the territory of the United States and its possessions and territories and all foreign countries; (ii) in and to any and all United States and foreign patent applications claiming priority to the Patents including, without limitation, applications for patents including provisionals, non-provisionals, divisions, continuations, continuations-in-part, requests for continued examinations, utility models, PCT applications and designs and any other related United States and foreign applications and equivalents thereof (the "Applications"), along with the right to claim priority to the Applications under any treaty relating thereto; (iii) in and to all United States and foreign patents, utility models, inventor's certificates and designs and all equivalents thereof which may be granted for the Patents or the Applications, including extensions, renewals, reissues and reexamination certificates thereof (the "Future Patents"); and (iv) in and to all rights to sue or claim for damages, injunctive reliefs and administrative reliefs and collect damages resulting from past, present and future infringement of any and all of the Patents and the Future Patents.

2. **Enjoyment and Assistance.** The Patents, the Applications and the Future Patents shall be held and enjoyed by Assignee, for Assignee's own use and benefit, and for Assignee's legal representatives and assigns, to the full end of the term or terms of the Patents and the Future Patents, as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made; and for the aforesaid consideration, Assignor hereby covenants, agrees and undertakes to execute promptly or cause to be executed promptly, whenever requested by Assignee, all patent applications, assignments, lawful oaths and any other papers which Assignee may deem necessary or desirable for securing to Assignee or for maintaining for Assignee all of the Patents, the Applications and the Future Patents hereby assigned or agreed to be assigned, all without further compensation to

EXECUTION VERSION

Assignor, but at the reasonable and pre-approved cost and expense of the Assignee, its successors, legal representatives, and assigns. It is agreed that Assignor shall be legally bound, upon request of Assignee or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the undersigned has knowledge or possession, relating to the making and practicing of the Patents and to testify in any legal proceeding relating thereto without further compensation to Assignor, but at the reasonable and pre-approved cost and expense of the Assignee, its successors, legal representatives, and assigns.

3. GENERAL.

3.1 Severability. If any term or provision of this Assignment or the application thereof to any circumstance shall, in any jurisdiction and to any extent, be invalid or unenforceable, such term or provision shall be ineffective as to such jurisdiction to the extent of such invalidity or unenforceability, without invalidating or rendering unenforceable such term or provision in any other jurisdiction, without affecting in any manner the application of such terms and provisions to circumstances other than those as to which it is held invalid or enforceable, and without affecting in any manner the remaining terms and provisions of this Assignment.

3.2 Entire Agreement. This Assignment, including the schedules attached hereto and the other agreements and documents referred to herein, contains the entire agreement and understanding of the parties hereto with respect to its subject matter and supersedes all prior and contemporaneous agreements and understandings, oral and written, among the parties with respect to such subject matter. To the extent any provision of this Assignment conflicts with any provision of the Purchase Agreement, the Purchase Agreement will govern.

3.3 Successors and Assigns. Neither this Assignment nor any of the rights, interests or obligations hereunder shall be transferred, conveyed or assigned, in whole or in part, by operation of law or otherwise, by either Party without the prior written consent of the other Party, except that Assignee may assign, in its sole discretion and without Assignor's consent this Assignment or its rights, interests and obligations under this Assignment, in whole or in part, to any third party. Any assignment not in accordance with the foregoing shall be void. Subject to the preceding sentences, this Assignment will be binding upon, inure to the benefit of and be enforceable by, the Parties and their respective permitted successors and assigns.

3.4 Waiver. Any term or provision of this Assignment may be waived in writing at any time by the party or parties entitled to the benefits thereof. No failure to exercise and no delay in exercising any right, power or privilege shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege preclude the exercise of any other right, power or privilege. No waiver of any breach of any covenant or agreement hereunder shall be deemed a waiver of any preceding or subsequent breach of the same or any other covenant or agreement.

3.5 Amendment. No supplement, modification, amendment or waiver of this Assignment shall be binding unless executed in writing by Assignee, on the one hand, and Assignor, on the other hand.

3.6 Construction. The parties hereto agree that they have been represented by counsel during the negotiation, preparation and execution of this Assignment and, therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in

EXECUTION VERSION

an agreement or other document will be construed against the party drafting such agreement or document.

3.7 Governing Law, Jurisdiction. This Assignment shall be governed by, and construed and enforced in accordance with, the laws of the State of California other than conflict of laws principles thereof directing the application of any law other than that of California. Courts within the State of California will have jurisdiction over all disputes between the parties hereto arising out of or relating to this Assignment and the agreements, instruments and documents contemplated hereby. The parties hereby consent to and agree to submit to the jurisdiction of such courts. Each of the parties hereto waives, and agrees not to assert in any such dispute, to the fullest extent permitted by applicable law, any claim that: (i) such party is not personally subject to the jurisdiction of such courts, (ii) such party and such party's property is immune from any legal process issued by such courts or (iii) any litigation commenced in such courts is brought in an inconvenient forum.

3.8 Counterparts. This Assignment may be executed in one or more counterparts, including electronically transmitted counterparts, each of which shall be deemed an original, but all such counterparts together shall constitute but one and the same Assignment.

[Signatures appear on next page]

IN WITNESS WHEREOF, intending to be legally bound hereby, the parties have caused this Assignment to be signed in their respective names by their duly authorized representatives as of the date first above set forth.

"Assignor"

CYLENE PHARMACEUTICALS, INC.

By: 

William G. Rice, Ph.D.
Acting Chief Executive Officer
Hereunto Duly Authorized

"See attached acknowledgment"

Notary Signature	
This instrument was acknowledged before me on _____ by _____ as an officer of Cylene Pharmaceuticals, Inc.	
(Seal, if any)	Signature: _____
	Name: _____
	Title: _____

"Assignee"

SENIHWA BIOSCIENCES, INC.

By: _____

Tai-Sen Soong, President and CEO
Hereunto Duly Authorized

Notary Signature	
This instrument was acknowledged before me on _____ by _____ as an officer of Senhwa Biosciences, Inc.	
(Seal, if any)	Signature: _____
	Name: _____
	Title: _____

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

STATE OF CALIFORNIA)
)
COUNTY OF SAN DIEGO) ss.

On April 29, 2013 before me, Tina M. Cox, Notary Public,
personally appeared William G. Rice

who proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing is true and correct.

WITNESS my hand and official seal.



Tina M. Cox
Signature of Notary Public

Place Notary Seal Above

OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.


Description of Attached Document

Title or Type of Document: Patent Assignment
Document Date: _____ Number of Pages: _____
Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer

Signer's Name: William G. Rice
 Individual
 Corporate Officer - Title(s): Acting Chief Executive Officer (Cylene Pharmaceuticals, Inc.)
 Partner - Limited General
 Attorney-in-Fact
 Trustee
 Guardian or Conservator
 Other: _____

Signer is representing: _____



IN WITNESS WHEREOF, intending to be legally bound hereby, the parties have caused this Assignment to be signed in their respective names by their duly authorized representatives as of the date first above set forth.

"Assignor"

CYLENE PHARMACEUTICALS, INC.

By: _____

William G. Rice, Ph.D.
Acting Chief Executive Officer
Hereunto Duly Authorized

Notary Signature

This instrument was acknowledged before me on _____ by _____ as an officer of
Cylene Pharmaceuticals, Inc.

Signature: _____

(Seal, if any)

Name: _____
Title: _____

"Assignee"

SENHWA BIOSCIENCES, INC.

By: _____

Tai-Sen Soong, President and CEO
Hereunto Duly Authorized

Notary Signature

This instrument was acknowledged before me on APR 29 2013 by Tai-Sen Soong as an officer of
Senhwa Biosciences, Inc.

Signature: _____

(Seal, if any)

Name: Chao Yuan-Sun
Title: Notary Public, Chao Yuan-Sun Notary
Public Office of Taiwan Taipei
District Court, Taiwan, Rep. of China.

901, NO. 346, NAN-KING B. RD., SEC 3, TAIPEI TAIWAN

Case No. 2852

SCHEDULE A

PATENTS

Country	Application No.	Application Date	Registration No.	Registration Date	Title/Mark
United States of America	61/143,282	1/8/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Australia	2009336141	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Brazil	PI0924041-1	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Canada	2,749,261	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
China	200980157884.9	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
European Patent Office	09789791.2	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Israel	213969	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
India	6025/DELNP/2011	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Japan	2011-545342	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Republic of Korea	10-2011-7018286	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Mexico	MX/a/2011/0007384	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS

New Zealand	594394	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Russian Federation	2011133093	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Singapore	201105005-1	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
Patent Cooperation Treaty	PCT/US2009/048948	6/10/2009			COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
South Africa	2011/05755	6/10/2009	2011/05755	4/25/2012	COMBINATION THERAPIES FOR NEOPLASTIC DISORDERS
United States of America	61/228,121	7/23/2009			TREATMENT OF NEOPLASTIC DISORDERS USING COMBINATION THERAPY
United States of America	61/282,079	11/17/2009			TREATMENT OF NEOPLASTIC DISORDERS USING COMBINATION THERAPIES
United States of America	12/684,063	1/7/2010			TREATMENT OF NEOPLASTIC DISORDERS USING COMBINATION THERAPIES
Australia	2010274165	7/7/2010			COMBINATION THERAPIES WITH CK2 MODULATORS
Brazil	BR112012001555-9	7/7/2010			COMBINATION THERAPIES WITH CK2 MODULATORS
Canada	2,768,631	7/7/2010			COMBINATION THERAPIES WITH CK2 MODULATORS
China	201080041258.7	7/7/2010			COMBINATION THERAPIES WITH CK2 MODULATORS
European Patent Office	10734398.0	7/7/2010			COMBINATION THERAPIES WITH CK2 MODULATORS
Israel	217630	7/7/2010			COMBINATION THERAPIES WITH CK2 MODULATORS
India	1620/DELNP/2012	7/7/2010			COMBINATION THERAPIES WITH CK2 MODULATORS

Japan	2012-521685	7/7/2010		COMBINATION THERAPIES WITH CK2 MODULATORS
Republic of Korea	10-2012-7004732	7/7/2010		COMBINATION THERAPIES WITH CK2 MODULATORS
Mexico	MX/a/2012/000949	7/7/2010		COMBINATION THERAPIES WITH CK2 MODULATORS
New Zealand	598338	7/7/2010		COMBINATION THERAPIES WITH CK2 MODULATORS
Russian Federation	2012108518	7/7/2010		COMBINATION THERAPIES WITH CK2 MODULATORS
Singapore	201200493-3	7/7/2010		COMBINATION THERAPIES WITH CK2 MODULATORS
Patent Cooperation Treaty	PCT/US2010/041244	7/7/2010		COMBINATION THERAPIES WITH CK2 MODULATORS
South Africa	2012/01341	7/7/2010		COMBINATION THERAPIES WITH CK2 MODULATORS
United States of America	60/842,061	9/1/2006		CASEIN KINASE MODULATORS
United States of America	60/844,542	9/13/2006		CASEIN KINASE AND PARP MODULATORS
United States of America	60/846,683	9/22/2006		THERAPEUTIC COMBINATIONS INCLUDING PARP MODULATORS
United States of America	60/873,936	12/7/2006		CASEIN KINASE AND PARP MODULATORS
United States of America	60/895,716	3/19/2007		CASEIN KINASE AND PARP MODULATORS
Australia	2007289065	8/31/2007		SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Brazil	PI0719123-5	8/31/2007		SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Canada	2,661,842	8/31/2007		SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
China	200780037330.6	8/31/2007		SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
European Patent Office	07841767.2	8/31/2007		SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS

Hong Kong	09110485.2	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Israel	197088	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
India	859/KOLNP/2009	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Japan	2009-526946	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Republic of Korea	10-2009-7006608	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Mexico	MX/a/2009/002298	8/31/2007	298175	4/13/2012	SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Norway	2009 0854	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
New Zealand	575548	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Russian Federation	2009111854	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
United States of America	11/849,230	8/31/2007	7,956,064	6/7/2011	FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Patent Cooperation Treaty	PCT/US2007/077464	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
South Africa	2009/01917	8/31/2007	2009/01917	3/31/2010	SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
Hong Kong	10102384.2	8/31/2007			SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
United States of America					SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
United States of America	13/035,640	2/25/2011			FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
United States of America	80/969,556	8/31/2007			THERAPEUTIC KINASE MODULATORS

Canada	2,698,463	8/29/2008			THERAPEUTIC KINASE MODULATORS
United States of America	12/201,692	8/29/2008	7,910,600	3/22/2011	THERAPEUTIC KINASE MODULATORS
Patent Cooperation Treaty	PCT/US2008/074820	8/29/2008			THERAPEUTIC KINASE MODULATORS
United States of America	61/067,945	2/29/2008			PROTEIN KINASE MODULATORS
United States of America	61/103,908	10/8/2008			PROTEIN KINASE MODULATORS
Australia	2009219154	2/28/2009			PROTEIN KINASE MODULATORS
Canada	2,716,755	2/28/2009			PROTEIN KINASE MODULATORS
China	200980115514.9	2/28/2009			PROTEIN KINASE MODULATORS
European Patent Office	09714461.2	2/28/2009			PROTEIN KINASE MODULATORS
Japan	2010-548932	2/28/2009			PROTEIN KINASE MODULATORS
Mexico	MX/a/2010/009445	2/28/2009			PROTEIN KINASE MODULATORS
New Zealand	588162	2/28/2009			PROTEIN KINASE MODULATORS
United States of America	12/296,084	3/2/2009	8,168,651	5/1/2012	PROTEIN KINASE MODULATORS
Patent Cooperation Treaty	PCT/US2009/035609	2/28/2009			PROTEIN KINASE MODULATORS
United States of America	13/315,103	12/8/2011			PROTEIN KINASE MODULATORS
United States of America	61/170,468	4/17/2009			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
United States of America	61/240,165	9/4/2009			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
United States of America	61/242,227	9/14/2009			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY

United States of America	61/297,669	1/23/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Australia	2010236162	4/16/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Brazil		4/16/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Canada	2,756,874	4/16/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
China	21080028807.2	4/16/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
European Patent Office	10765314.9	4/16/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Israel	215712	4/16/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
India	8085/DELNP/2011	4/16/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Japan	2012-565989	4/16/2010			METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY

Republic of Korea	10-2011-7027302	4/16/2010		METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Mexico	MX/w/2011/010918	4/16/2010		METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
New Zealand	596429	4/16/2010		METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Russian Federation	2011148544	4/16/2010		METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Singapore	201107474-7	4/16/2010		METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
United States of America	12/782,038	4/16/2010		METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
Patent Cooperation Treaty	PCT/US2010/031520	4/16/2010		METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
South Africa	2011/07773	4/16/2010		METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN KINASE CK2 ACTIVITY
United States of America	61/180,090	5/20/2009		PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
United States of America	61/218,318	6/18/2009		PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS

Australia	2010249493	5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Brazil	PI1011066-6	5/20/2009			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Canada	2,762,313	5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
China	201080032306.5	5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
European Patent Office	10778418.3	5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Israel	216411				PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
India	9273/DELNP/2011	5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Japan	2012-512047	5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Republic of Korea	10-2011-7030314	5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Mexico	MX/a/2011/012369				PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
New Zealand	596571	5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Russian Federation		5/20/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Singapore	201108587-5				PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
United States of America	12/784,271	5/20/2010	8,367,681	2/5/2013	PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS

Patent Cooperation Treaty	PCT/US2010/035 657	5/20/2010		PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
South Africa	2011/08622	6/20/2010		PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
United States of America	61/173,996	5/20/2009		RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
United States of America	61/218,314	6/18/2009		RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
United States of America	12/819,091	6/18/2010		RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Patent Cooperation Treaty	PCT/US2010/039 249	6/18/2010		RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
Russian Federation	2012114002	9/10/2010		PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS
Singapore	201201692-9	9/10/2010		PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS
United States of America	12/879,851	9/10/2010		PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS
Patent Cooperation Treaty	PCT/US2010/048 441	9/10/2010		PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS
South Africa	2012/02618	9/10/2010		PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS
United States of America	13/207,700	8/11/2011		PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS
United States of America	61/180,099	5/20/2009		NOVEL PROTEIN KINASE MODULATORS

United States of America	61/218,347	6/18/2009			NOVEL PROTEIN KINASE MODULATORS
United States of America	61/297,646	12/17/2009			NOVEL PROTEIN KINASE MODULATORS
United States of America	12/784,055	5/20/2010			NOVEL PROTEIN KINASE MODULATORS
Patent Cooperation Treaty	PCT/US2010/035644	5/20/2010			NOVEL PROTEIN KINASE MODULATORS
United States of America	61/283,638	11/23/2009			POLYMORPHS AND SALTS OF A KINASE INHIBITOR
United States of America	12/952,879	11/23/2010			POLYMORPHS AND SALTS OF A KINASE INHIBITOR
Patent Cooperation Treaty	PCT/US2010/057838	11/23/2010			POLYMORPHS AND SALTS OF A KINASE INHIBITOR
United States of America	61/237,227	6/26/2009			NOVEL PROTEIN KINASE MODULATORS
United States of America	61/299,317	12/22/2009			NOVEL PROTEIN KINASE MODULATORS
Australia	2010286691	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
Brazil		8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
Canada	2,771,890	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
China	201080047400.8	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
European Patent Office	10749732.3	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
Israel	218280	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
India	2596/DELNP/2012	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS

Japan	2012-526972	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
Republic of Korea	10-2012-7007386	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
Mexico	MX/a/2012/002426	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
New Zealand	599002	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
Russian Federation	2012111255	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
Singapore	201201284-5	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
United States of America	12/989,335	8/26/2010			NOVEL PROTEIN KINASE MODULATORS
Patent Cooperation Treaty	PCT/US2010/048760	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
South Africa	2012/02171	8/26/2010			CONDENSED QUINOLINES AS PROTEIN KINASE MODULATORS
United States of America	61/243,107	9/16/2009			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Australia	2010295622	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Brazil	BR112012005957-2	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Canada	2,774,148	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
China	201080049956.0	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF

European Patent Office	10817825.2	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Israel	218632	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
India	3213/DELNP/2012	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Japan	2012-529901	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Republic of Korea	10-2012-7009466	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Mexico	MX/a/2012/003316	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
New Zealand	599403	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Russian Federation	2012114777	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Singapore	201201643-8	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
United States of America	12/883,703	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
Patent Cooperation Treaty	PCT/US2010/049116	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
South Africa	2012/02731	9/16/2010			TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
United States of America	61/248,279	10/2/2009			BIOMARKERS FOR SENSITIVITY OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS

United States of America	61/255,805	10/28/2009			BIOMARKERS FOR SENSITIVITY OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
United States of America	61/323,771	4/13/2010			BIOMARKERS FOR SENSITIVITY OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
United States of America	61/380,685	9/7/2010			BIOMARKER FOR SENSITIVITY OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Australia		10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Brazil	BR11201200765 5-1	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Canada	2,776,278	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
China	201080054768.1	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
European Patent Office	10765546.6	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Israel	218935	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS

India	3817/DELNP/2012	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Japan	2012-632136	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Republic of Korea	10-2012-7011401	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Mexico	MX/a/2012/003997	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
New Zealand	599698	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Russian Federation	2012117802	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
Singapore	201202398-2	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
United States of America	12/897,840	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS

Patent Cooperation Treaty	PCT/US2010/051341	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
South Africa	2012/03182	10/4/2010			BIOMARKERS FOR PREDICTING THE SENSITIVITY AND RESPONSE OF PROTEIN KINASE CK2-MEDIATED DISEASES TO CK2 INHIBITORS
United States of America	61/243,104	9/16/2009			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Australia	2010295619	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Brazil	BR112012005970-0	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Canada	2,774,266	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
China	201060049960.7	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
European Patent Office	10617824.5	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Israel	218631	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
India	3217/DELNP/2012	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Japan	2012-529900	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Republic of Korea	10-2012-7009482	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Mexico	MX/a/2012/003322	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
New Zealand	599400	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Russian Federation	2012114640	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Singapore	201201845-3	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS

United States of America	12/983,688	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
Patent Cooperation Treaty	PCT/US2010/049113	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
South Africa	2012/02729	9/16/2010			NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
United States of America	61/266,801	12/4/2009			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
United States of America	61/354,165	6/11/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Australia	2010326268	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Brazil	BR112012013508-2	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Canada	2,782,684	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
China	201080063054.2	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
European Patent Office	10834934.1	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Israel	220086	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
India	5933/DELNP/2012	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Japan	2012-542060	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Republic of Korea	10-2012-7017450	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS

Mexico	MX/a/2012/008419	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
New Zealand	601028	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Russian Federation	2012127792	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Singapore	201204103-4	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
United States of America	12/946,759	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Patent Cooperation Treaty	PCT/US2010/056712	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
South Africa	2012/04976	11/15/2010			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
United States of America	61/405,815	10/22/2010			DEUTERATED SERINE-THREONINE PROTEIN KINASE MODULATORS
United States of America	13/242,525	9/23/2011			DEUTERATED SERINE-THREONINE PROTEIN KINASE MODULATORS
Patent Cooperation Treaty	PCT/US2011/056725	10/18/2011			DEUTERATED SERINE-THREONINE PROTEIN KINASE MODULATORS
United States of America	61/494,660	6/8/2011			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
Patent Cooperation Treaty	PCT/US2012/041567	6/8/2012			PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS

Country	Application No.	Application Date	Registration No.	Registration Date	Title/Mark
United States of America	60/511,030	9/17/2004			NOVEL BENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF
United States of America	60/638,603	12/22/2004			AZA-BENZO(C)-FLUOREN-5-ONE ANALOGS
United States of America	60/688,796	6/9/2005			AZA-BENZO(C)-FLUOREN-5-ONE ANALOGS
United States of America	60/688,866	6/9/2005			NOVEL BENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF
Australia	2005286965	9/16/2005	2005286965	2/4/2010	QUINOLONE ANALOGS AS CELL PROLIFERATION INHIBITORS
Brazil	PI0515319-0	9/16/2005			QUINOLONE ANALOGS
Canada	2,560,749	9/16/2005			QUINOLONE ANALOGS AS CELL PROLIFERATION INHIBITORS
China	200580039209.8	9/16/2005			QUINOLONE ANALOGS AS CELL PROLIFERATION INHIBITORS
European Patent Office	05813754.8	9/16/2005			QUINOLONE ANALOG AS CELL PROLIFERATION INHIBITORS
Hong Kong	07112621.5	9/16/2005			QUINOLONE ANALOG AS CELL PROLIFERATION INHIBITORS
Israel	181857	9/16/2005			QUINOLONE ANALOGS
India	1002/KOLNP/2007	9/16/2005			QUINOLONE ANALOGS

Japan	2007-532545	9/16/2005			QUINOLONE ANALOGS
Republic of Korea	10-2007-7008765	9/16/2005	10-989029	10/14/2010	QUINOLONE ANALOGS AS CELL PROLIFERATION INHIBITORS
Mexico	MX/a/2007/003282	9/16/2005			QUINOLONE ANALOGS
Norway	2007 1942	9/16/2005			QUINOLONE ANALOGS
New Zealand	553746	9/16/2005	553746	10/7/2010	QUINOLONE ANALOGS
Russian Federation	2007114301	9/16/2005	2349566	3/20/2009	QUINOLONE ANALOGS
United States of America	11/149,007	6/9/2005	7,652,134	1/26/2010	METHODS FOR CONVERTING QUINOLONE ESTERS INTO QUINOLONE AMIDES
Patent Cooperation Treaty	PCT/US2005/033323	9/16/2005			QUINOLONE ANALOGS
South Africa	2007/02157	9/16/2005	2007/2157	11/26/2008	QUINOLONE ANALOGS AS CELL PROLIFERATION INHIBITORS
European Patent Office		9/16/2005			QUINOLONE ANALOG AS CELL PROLIFERATION INHIBITORS
Hong Kong	08104432.0	9/16/2005			QUINOLONE ANALOGS AS CELL PROLIFERATION INHIBITORS
United States of America	11/228,636	9/16/2005	7,816,406	10/19/2010	QUINOLONE ANALOGS
United States of America					AZA-BENZO(C)-FLUOREN-5-ONE ANALOGS

Patent Cooperation Treaty					AZA-BENZO(C)-FLUOREN-5-ONE ANALOGS
United States of America	60/705,966	8/5/2005			METHODS OF PREPARING QUINOLONE ANALOGS
European Patent Office	06789386.7	8/4/2006			METHODS OF PREPARING QUINOLONE ANALOGS
Hong Kong	08113436.7	8/4/2006			METHODS OF PREPARING QUINOLONE ANALOGS
United States of America	11/499,076	8/4/2006	7,816,524	10/19/2010	METHODS OF PREPARING QUINOLONE ANALOGS
Patent Cooperation Treaty	PCT/US2006/030409	8/4/2006			METHODS OF PREPARING QUINOLONE ANALOGS
United States of America	12/274,302	11/19/2008	7,834,180	11/16/2010	METHODS OF PREPARING QUINOLONE ANALOGS
United States of America	60/801,550	5/17/2006			TETRACYCLIC IMIDAZOLE ANALOGS
European Patent Office	07866283.8	5/17/2007			TETRACYCLIC IMIDAZOLE ANALOGS
United States of America	12/301,080	5/17/2007			TETRACYCLIC IMIDAZOLE ANALOGS
Patent Cooperation Treaty	PCT/US2007/069186	5/17/2007			TETRACYCLIC IMIDAZOLE ANALOGS
United States of America	60/811,990	6/8/2006			PYRIDINONE ANALOGS
United States of America	12/303,952	6/8/2007			PYRIDINONE ANALOGS
Patent Cooperation Treaty	PCT/US2007/070774	6/6/2007			PYRIDINONE ANALOGS

United States of America	60/811,992	6/8/2006		QUINOLONE ANALOGS DERIVATIZED WITH SULFONIC ACID, SULFONATE OR SULFONAMIDE
United States of America	60/904,694	3/1/2007		QUINOLONE ANALOGS DERIVATIZED WITH SULFONIC ACID, SULFONATE OR SULFONAMIDE
United States of America	12/303,957	6/8/2007		QUINOLONE ANALOGS DERIVATIZED WITH SULFONIC ACID, SULFONATE OR SULFONAMIDE
Patent Cooperation Treaty	PCT/US2007/070794	6/8/2007		QUINOLONE ANALOGS DERIVATIZED WITH SULFONIC ACID, SULFONATE OR SULFONAMIDE
United States of America	60/912,411	4/17/2007		HYDRAZIDE COMPOUNDS AND USES THEREOF
United States of America	12/596,240	4/17/2008		HYDRAZIDE COMPOUNDS AND USES THEREOF
Patent Cooperation Treaty	PCT/US2006/060877	4/17/2008		HYDRAZIDE COMPOUNDS AND USES THEREOF
United States of America	60/978,042	10/5/2007		ORALLY BIOAVAILABLE RIBOSOMAL RNA BIOSYNTHESIS INHIBITORS
United States of America	61/038,681	3/21/2008		ORALLY BIOAVAILABLE RIBOSOMAL RNA BIOSYNTHESIS INHIBITORS
United States of America	61/045,933	4/17/2008		ORALLY BIOAVAILABLE RIBOSOMAL RNA BIOSYNTHESIS INHIBITORS
Australia	2008306485	10/3/2008		QUINOLONE ANALOGS AND METHODS RELATED THERETO
Brazil	PI0817806-2	10/3/2008		QUINOLONE ANALOGS AND METHODS RELATED THERETO

Canada	2,701,630	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
China	200880119635.8	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
European Patent Office	08935342.0	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
Hong Kong	11104885.7	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
Israel	204844	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
India	1479/KOLNP/2010	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
Japan	2010-528194	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
Republic of Korea	10-2010-7008924	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
Mexico	MX/a/2010/003685	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
Norway	20100596	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
New Zealand	584892	10/3/2008	584892	10/8/2012	QUINOLONE ANALOGS AND METHODS RELATED THERETO
Russian Federation	2010117225	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
United States of America	12/245,619	10/3/2008	7,928,100	4/19/2011	QUINOLONE ANALOGS AND METHODS RELATED THERETO

Patent Cooperation Treaty	PCT/US2008/078659	10/3/2008			QUINOLONE ANALOGS AND METHODS RELATED THERETO
South Africa	2010/02966	10/3/2008	2010/02966	1/26/2011	QUINOLONE ANALOGS AND METHODS RELATED THERETO
United States of America	13/043,956	3/9/2011			QUINOLONE ANALOGS AND METHODS RELATED THERETO

DB2/24049772.4